Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
Completed · Phase 1 · Has a placebo group
Conditions studied: Rheumatoid Arthritis
In brief
This is a randomized, double-blind, placebo-controlled, single-dose, dose escalation study in healthy male and or female subjects and subjects with Rheumatoid Arthritis (RA) to determine the safety and tolerability of MORAb-022.
Key facts
- Study ID
- NCT01357759
- Run by
- Morphotek
- People needed
- 20
- Starts
- 2013-05-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2015-11-16
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Axis Clinical Trials — Los Angeles, California, United States
- Seaview Jacksonville, LLC — Jacksonville, Florida, United States
- Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
- Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
- Pharmaceutical Research Associates Group B.V. — Zuidlaren, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.